PD-1/PD-L1在非小细胞肺癌中的作用及研究进展

Research Progress and the Role of PD-1/PD-L1 in Non-small Cell Lung Cancer

近年来,免疫治疗在非小细胞肺癌中的价值引起了大量的关注。2012年首个证实PD-1/PD-L1阻断剂对既往反复治疗过的晚期非小细胞肺癌有疗效的报道激发了后续大量的相关研究。MPDL3280a、MEDI-4736、BMS-936559、Nivolumab、Pembrolizumab等PD-1/PD-L1抗体在Ⅰ期临床试验中显示出较好的疗效及良好的耐受性,治疗前景值得期待,Ⅲ期临床试验亦在进一步探索其临床应用价值。文章对PD-1/PD-L1在非小细胞肺癌中的作用机制、研究进展及今后研究方向作一综述。

In recent years,there has been a mounting enthusiasm in immunotherapy for non-small cell lung cancer （NSCLC）. Since the first report about the response of previously treated NSCLC patients treated with PD-1/PD-L1 inhibitor had been published in 2012,a mount of researches were promoted. Several PD-1/PD-L1 antibodies,including MPDL3280a,MEDI-4736,BMS- 936559,Nivolumab and Pembrolizumab,etc.have shown considerable responses and well tolerance in phase I studies. Phase HI clinical trials are ongoing to explore their clinical values. This review summarizes the role of PD-1/PD-L1 in NSCLC as well as its current status and future direction.